In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry

Summary

The REG1 system consists of factor IXa inhibitor, RB006, an ap-tamer-based anticoagulant and its antidote, RB007. The optimal use of RB006 can be facilitated by understanding its effect on the formation of thrombin and fibrin, and other standard tests of coagulation. Blood from consented volunteers was drawn into 3.2% citrate (9:1 v/v) and either used immediately or centrifuged to obtain platelet-poor plasma. Increasing concentrations of ap-tamer (6–24 μg/ml) alone or in combination with heparin (0.1 U/ml) or lepirudin (0.2 μg/ml) were added to blood and plasma samples. Activated clotting times (ACT+, low range-ACT), thrombelastometry (ROTEM™) or thrombelastography (TEG^®) were performed in recalcified whole blood samples. Thrombin generation, prothrombin time (PT) and activated partial thromboplastin time (aPTT) were performed in plasma samples. To some samples the antidote RB007 was added to neutralise the anticoagulation activity of RB006. In all experiment the ratio of RB006 to RB007 was kept 1:2. RB006 dose-dependently prolonged aPTT and low range-ACT, but, as expected, had no effect on PT. RB006 prolonged the lag time and decreased the peak of Actin-triggered thrombin generation. Thrombin-activated TEG demonstrated that RB006 decreases the rate of clot formation. These effects were potentiated when RB006 was combined with heparin or lepirudin. In all experiments RB007 reversed the effects of RB006 back to baseline. In conclusion, RB006 inhibits thrombin generation and clot formation in a concentration-dependent manner. It is feasible to monitor RB006 and its reversal with RB007 using aPTT, low range-ACT, and thrombin-activated TEG.

Keywords

Anticoagulation - aptamer - factor IXa inhibition - thrombin inhibition

• References

• 1 Howard EL, Becker KCD, Rusconi CP. et al. Factor IXa inhibitors as novel anticoagulants. Arteriosclerosis Thromb Vasc Biol 2007; 27: 722-727.
• 2 Rusconi CP, Scardino E, Layzer J. et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002; 419: 90-94.
• 3 Gopinath SCB, Shikamoto Y, Mizuno H. et al. A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway. Thromb Haemost 2006; 95: 767-771.
• 4 Brummel KE, Paradis SG, Butenas S. et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-152.
• 5 Segal JB, Dzik WH. Transfusion Medicine/Hemostasis Clinical Trials N Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45: 1413-1425.
• 6 Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 2004; 41: 20-24.
• 7 Nimjee SM, Keys JR, Pitoc GA. et al. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Thera 2006; 14: 408-415.
• 8 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 9 Kawasaki J, Katori N, Kodaka M. et al. Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg 2004; 99: 1440-1444.
• 10 Tanaka KA, Taketomi T, Szlam F. et al. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg 2008; 106: 732-738.
• 11 Butenas S, Mann KG. Blood coagulation. Biochemistry 2002; 67: 3-12.
• 12 Wielders SJH, Beguin S, Hemker HC. et al. Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. Arteriosclerosis Thromb Vasc Biol 2004; 24: 1138-1142.
• 13 Taketomi T, Szlam F, Bader SO. et al. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. Blood Coagul Fibrinolysis 2008; 19: 135-141.
• 14 Szlam F, Taketomi T, Sheppard CA. et al. Anti-thrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. Anesth Analg 2008; 106: 719-724.
• 15 Bates SM, Weitz JI. New anticoagulants: Beyond heparin, low-molecular-weight heparin and warfarin. Brit J Pharmacol 2005; 144: 1017-1028.
• 16 Spanier TB, Chen JM, Oz MC. et al. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998; 116: 860-869.
• 17 Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 2003; 102: 953-955.
• 18 Kleinschnitz C, Stoll G, Bendszus M. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
• 19 Gui T, Reheman A, Funkhouser WK. et al. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Thromb Res 2007; 121: 225-234.
• 20 Salomon O, Steinberg DM, Koren-Morag N. et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-4117.
• 21 Spanier TB, Oz MC, Minanov OP. et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg 1998; 115: 1179-1188.
• 22 Chung JH, Gikakis N, Rao AK. et al. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996; 93: 2014-2018.
• 23 Spanier TB, Oz MC, Madigan JD. et al. Selective anticoagulation with active site blocked factor IXa in synthetic patch vascular repair results in decreased blood loss and operative time. ASAIO J 1997; 43: M526-530.
• 24 Boisclair MD, Lane DA, Philippou H. et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-3357.